Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1950 3
1953 1
1954 3
1957 2
1958 1
1961 1
1962 3
1963 1
1965 2
1966 1
1967 3
1968 1
1969 1
1970 1
1971 2
1972 1
1973 2
1976 1
1978 2
1979 2
1980 11
1981 6
1982 9
1983 7
1984 9
1985 6
1986 6
1987 7
1988 11
1989 12
1990 12
1991 10
1992 22
1993 15
1994 22
1995 18
1996 13
1997 21
1998 19
1999 17
2000 9
2001 28
2002 19
2003 37
2004 32
2005 40
2006 48
2007 56
2008 27
2009 25
2010 34
2011 27
2012 28
2013 22
2014 24
2015 32
2016 30
2017 39
2018 27
2019 29
2020 38
2021 41
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

914 results
Results by year
Filters applied: . Clear all
Page 1
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G. Moro-Sibilot D, et al. Among authors: ferretti g. Ann Oncol. 2019 Dec 1;30(12):1985-1991. doi: 10.1093/annonc/mdz407. Ann Oncol. 2019. PMID: 31584608 Free article. Clinical Trial.
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.
Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY. Mazieres J, et al. Among authors: ferretti gr. Ann Oncol. 2020 Feb;31(2):289-294. doi: 10.1016/j.annonc.2019.10.022. Epub 2020 Jan 3. Ann Oncol. 2020. PMID: 31959346 Free article.
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
Rossi V, Berchialla P, Giannarelli D, Nisticò C, Ferretti G, Gasparro S, Russillo M, Catania G, Vigna L, Mancusi RL, Bria E, Montemurro F, Cognetti F, Fabi A. Rossi V, et al. Among authors: ferretti g. Cancers (Basel). 2019 Oct 26;11(11):1661. doi: 10.3390/cancers11111661. Cancers (Basel). 2019. PMID: 31717791 Free PMC article.
The role of paraoxonase in cancer.
Bacchetti T, Ferretti G, Sahebkar A. Bacchetti T, et al. Among authors: ferretti g. Semin Cancer Biol. 2019 Jun;56:72-86. doi: 10.1016/j.semcancer.2017.11.013. Epub 2017 Nov 21. Semin Cancer Biol. 2019. PMID: 29170064 Review.
Baroreflex sensitivity: An algebraic dilemma.
Taboni A, Fagoni N, Vinetti G, Ferretti G. Taboni A, et al. Among authors: ferretti g. Acta Physiol (Oxf). 2018 Mar;222(3). doi: 10.1111/apha.12979. Epub 2017 Oct 30. Acta Physiol (Oxf). 2018. PMID: 29024446 No abstract available.
Imaging in the aftermath of COVID-19: what to expect.
Ebner L, Funke-Chambour M, von Garnier C, Ferretti G, Ghaye B, Beigelman-Aubry C. Ebner L, et al. Among authors: ferretti g. Eur Radiol. 2021 Jun;31(6):4390-4392. doi: 10.1007/s00330-020-07465-6. Epub 2020 Dec 28. Eur Radiol. 2021. PMID: 33372242 Free PMC article. No abstract available.
Through the forest of motor representations.
Ferretti G. Ferretti G. Conscious Cogn. 2016 Jul;43:177-96. doi: 10.1016/j.concog.2016.05.013. Epub 2016 Jun 14. Conscious Cogn. 2016. PMID: 27310110 Review.
Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues.
Ferraz da Costa DC, Pereira Rangel L, Martins-Dinis MMDDC, Ferretti GDDS, Ferreira VF, Silva JL. Ferraz da Costa DC, et al. Among authors: ferretti gdds. Molecules. 2020 Feb 18;25(4):893. doi: 10.3390/molecules25040893. Molecules. 2020. PMID: 32085381 Free PMC article. Review.
914 results